GlobeNewswire Inc | Jun 14, 2021 08:30AM EDT

June 14, 2021

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it will be presenting at the Raymond James Human Health Innovation Conference on June 21st, 2021.

Ken dEntremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer, will present a Company overview and provide a business update. The presentation will be webcast live and available for replay on the Companys website atwww.medexus.com/en_US/investors/news-events.

Raymond James Human Health Innovation ConferenceDate: Monday, June 21, 2021 Time: 2:40 P.M. Eastern Time

In addition to the presentation, management will be participating in virtual one-on-one meetings throughout the conference. Interested investors should contact their Raymond James representatives to schedule a meeting.

About Medexus

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Companys vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Companys leading products are: Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken dEntremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:ken.dentremont@medexus.com

Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail:roland.boivin@medexus.com

Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email:mdp@crescendo-ir.com

Investor Relations (Canada):Tina ByersAdelaide CapitalTel: 905-330-3275E-mail:tina@adcap.ca